Loading…
Minerva Neurosciences, Inc. is projected to rise to $5.95 by 2027, a +13% move from its current price of $5.26. NERV is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $5.03 | $5.26 | $5.50 | -0.06% |
| May 30 | $4.93 | $5.25 | $5.60 | -0.12% |
| May 31 | $4.86 | $5.25 | $5.68 | -0.18% |
| Jun 1 | $4.79 | $5.25 | $5.74 | -0.24% |
| Jun 2 | $4.74 | $5.24 | $5.80 | -0.29% |
| Jun 3 | $4.69 | $5.24 | $5.85 | -0.35% |
| Jun 4 | $4.65 | $5.24 | $5.90 | -0.41% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $4.65 | $5.24 | $5.90 | -0.41% |
| Week 2 | $4.41 | $5.22 | $6.18 | -0.82% |
| Week 3 | $4.22 | $5.20 | $6.39 | -1.23% |
| Week 4 | $4.08 | $5.17 | $6.57 | -1.64% |
| Week 5 | $3.95 | $5.15 | $6.73 | -2.05% |
| Week 6 | $3.83 | $5.13 | $6.87 | -2.45% |
| Week 7 | $3.73 | $5.11 | $7.01 | -2.85% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company in the Healthcare sector focusing on the development and commercialization of product candidates for central nervous system diseases. Its lead product candidate is roluperidone, which is in Phase 3 confirmatory trial for the treatment of negative symptoms in patients with schizophrenia.
The company was incorporated in 2007 and is based in Burlington, Massachusetts.
Minerva Neurosciences, Inc. (NERV) is currently priced at $5.26 per share and has a market capitalization of $245.06M. It is positioned with a rank of 3694 in the market. The asset operates in the Healthcare space and has a lead candidate in late-stage development, roluperidone, for schizophrenia.
The current price sits at the forecast’s 2026 average level, with long-run upside implied by the year-by-year forecast.
A major floor 49.3% below — a decisive break under it would weaken the trend.
The nearest floor, 17.1% below — buyers have tended to step in here.
The nearest ceiling, 39.7% above — a clean break opens room to run.
A major ceiling 64.4% above — clearing it would confirm fresh momentum.
Key NERV support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NERV market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $5.21 | Buy | $5.20 | Buy |
| MA 10 | $5.14 | Buy | $5.27 | Sell |
| MA 20 | $5.62 | Sell | $5.52 | Sell |
| MA 50 | $6.06 | Sell | $5.82 | Sell |
| MA 100 | $5.79 | Sell | $5.56 | Sell |
| MA 200 | $4.48 | Buy | $4.78 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.88 | Neutral |
| Stoch RSI (14) | 85.55 | Sell |
| CCI (20) | -50.11 | Neutral |
| Williams %R (14) | -49.01 | Info |
| MACD (12,26,9) | -0.02 | Sell |
| ROC (12) | -10.54 | Sell |
| Bollinger %B (20,2) | 0.34 | Neutral |
| Stochastic %K (14) | 50.99 | Neutral |
| TRIX (15) | -0.70 | Sell |
| Awesome (5,34) | -0.73 | Sell |
| Ultimate (7,14,28) | 44.75 | Neutral |
| Momentum (10) | -0.34 | Sell |
| Aroon Osc (25) | -76.00 | Sell |
| Hull MA (9) | 5.34 | Sell |
| ADX (14) | 19.32 | Neutral |
| ATR (14) | 0.21 | Info |
The near-term technical picture is BULLISH, with RSI(14) at 40. The stock trades around the key moving averages, with SMA50 at $6.17 and SMA200 at $4.44. A support level is identified at $4.36 and a resistance level at $7.35. Over the last 30 days, the price range has been from $3.83 to $7.21.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.90 | $5.26 | $7.03 | 0% | Neutral | |
| $4.42 | $5.95 | $8.63 | +13% | Neutral | |
| $5.57 | $7.86 | $12.03 | +49% | Bullish | |
| $6.86 | $10.10 | $16.11 | +92% | Bullish | |
| $7.35 | $11.22 | $18.55 | +113% | Bullish | |
| $6.67 | $10.55 | $17.97 | +100% | Bullish | |
| $7.12 | $11.64 | $20.37 | +121% | Bullish | |
| $7.40 | $12.48 | $22.39 | +137% | Bullish | |
| $6.89 | $11.97 | $21.96 | +128% | Bullish | |
| $9.45 | $16.93 | $31.69 | +222% | Bullish | |
| $9.72 | $20.00 | $40.77 | +280% | Bullish | |
| $23.92 | $53.15 | $122.26 | +911% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $3.90 | $5.26 | $6.24 | +0.00% |
| June 2026 | $4.30 | $5.13 | $6.31 | -2.50% |
| July 2026 | $4.13 | $4.98 | $6.26 | -2.81% |
| August 2026 | $4.31 | $5.26 | $6.72 | +5.57% |
| September 2026 | $4.37 | $5.39 | $6.98 | +2.42% |
| October 2026 | $4.10 | $5.10 | $6.68 | -5.35% |
| November 2026 | $4.02 | $5.04 | $6.67 | -1.26% |
| December 2026 | $4.16 | $5.26 | $7.03 | +4.35% |
Click any year to see its month-by-month NERV forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NERV could reach as high as $7.03, with a base case around $5.26 and support toward $3.90 — roughly 0% from $5.26. Price action looks broadly range-bound.
Expect NERV to range from $4.42 to $8.63 through 2027. The $5.95 average target implies a +13% move from current prices. That is up +13% on the projected 2026 average. A consolidation phase looks the most probable path here.
The NERV price prediction for 2028 points to an average of $7.86 (low $5.57, high $12.03) — a potential gain of +49% on today's $5.26. Momentum favours further upside here.
In 2029, NERV is projected to trade between $6.86 and $16.11, averaging $10.10 — a potential gain of +92% from today's $5.26. That is up +28% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Minerva Neurosciences, Inc.'s 2030 outlook centres on $11.22, within a $7.35 to $18.55 range. That is up +11% on the projected 2029 average. That marks a +113% change versus current levels. Momentum favours further upside here.
By 2031, NERV could reach as high as $17.97, with a base case around $10.55 and support toward $6.67 — roughly +100% from $5.26. Buyers look set to stay in control over this stretch.
Expect NERV to range from $7.12 to $20.37 through 2032. The $11.64 average target implies a +121% move from current prices. That is up +10% on the projected 2031 average. Momentum favours further upside here.
The NERV price prediction for 2033 points to an average of $12.48 (low $7.40, high $22.39) — a potential gain of +137% on today's $5.26. Buyers look set to stay in control over this stretch.
In 2034, NERV is projected to trade between $6.89 and $21.96, averaging $11.97 — a potential gain of +128% from today's $5.26. That is -4% versus the projected 2033 average. Momentum favours further upside here.
Minerva Neurosciences, Inc.'s 2035 outlook centres on $16.93, within a $9.45 to $31.69 range. That is up +41% on the projected 2034 average. That marks a +222% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NERV could reach as high as $40.77, with a base case around $20.00 and support toward $9.72 — roughly +280% from $5.26. Momentum favours further upside here.
Expect NERV to range from $23.92 to $122.26 through 2050. The $53.15 average target implies a +911% move from current prices. That is up +166% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NERV today (≈ 190.114068 NERV) could be worth
$10,105.5
+$9,105.5 (+911%) by 2050 · US Dollar
Based on the average projected NERV price of $53.15 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NERVwould be worth at today's price.
$1,000 invested in NERV on May 27, 2025 (≈ 671.140935 NERV) would be worth
$3,530.2
+$2,530.2 (+253.0%) today · 3.53× · US Dollar
Based on a NERV entry price of $1.49 vs. today's $5.26.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $5.03 | $1,045.73 | +4.6% |
| 1 month ago | $6.43 | $818.04 | -18.2% |
| 3 months ago | $6.23 | $844.3 | -15.6% |
| 6 months ago | $4.18 | $1,258.37 | +25.8% |
| 1 year ago | $1.49 | $3,530.2 | +253.0% |
| All time (5.0y) ago | $23.76 | $221.38 | -77.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NERV forecast.
Our base-case forecast reaches $11.00 around 2030.
Implied market cap at $11.00: $512.48M
The multi-year forecast shows a path of growth with rising averages and sizable upside. In 2026 the avg is $5.26 with a min of $3.90 and a max of $7.09, and a neutral sentiment. By 2027 the avg rises to $5.89 (max $8.66, min $4.33) with a 12% ROI.
The forecast strengthens through 2028-2030 to a 2030 avg of $11.36 (max $19.13) and a 115.9% ROI, continuing bullish momentum through 2031-2035 and beyond. Notably, the 2032-2034 period shows higher averages with 2032 avg $11.85 and 2033 avg $12.56, and 2035 avg $17.48 (max $33.52). The outlook extends to 2040 with avg $20.48 (max $42.87, ROI 289.3%) and to 2050 with avg $55.05 (max $126.62, ROI 946.7%), all under a bullish designation.
These figures reflect estimates of future price paths and are not guarantees; actual results can differ due to market conditions and other factors.
Tap a question to reveal the answer.
The forecast for 2030 shows an avg of $11.36 with a min of $7.27 and a max of $19.13, and a projected ROI of 115.9% with a bullish sentiment.
The forecast displays a bullish sentiment from 2028 onward, with rising averages and higher ROIs, culminating in a 2050 avg of $55.05 and a max of $126.62 (ROI 946.7%). Note that 2026 shows a neutral stance with an avg of $5.26.
Yes. The forecast max reaches $21.20 in 2032 and $23.03 in 2033, indicating it can exceed $20 in later years.
Current price is $5.26 per share and market cap is $245.06M.
The long-term forecast envisions an avg price of $55.05 by 2050 with a max of $126.62 and a ROI of 946.7% under bullish conditions.
Minerva Neurosciences, Inc. Community Discussion
0Share your Minerva Neurosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.